JP2013526525A - レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法 - Google Patents

レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法 Download PDF

Info

Publication number
JP2013526525A
JP2013526525A JP2013510219A JP2013510219A JP2013526525A JP 2013526525 A JP2013526525 A JP 2013526525A JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013526525 A JP2013526525 A JP 2013526525A
Authority
JP
Japan
Prior art keywords
day
administered
amount
days
azacytidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526525A5 (https=
Inventor
ビー． ゼルディス ジェロメ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013526525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2013526525A publication Critical patent/JP2013526525A/ja
Publication of JP2013526525A5 publication Critical patent/JP2013526525A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013510219A 2010-05-11 2011-05-10 レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法 Pending JP2013526525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/777,765 US8404716B2 (en) 2002-10-15 2010-05-11 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US12/777,765 2010-05-11
PCT/US2011/035822 WO2011143147A1 (en) 2010-05-11 2011-05-10 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine

Publications (2)

Publication Number Publication Date
JP2013526525A true JP2013526525A (ja) 2013-06-24
JP2013526525A5 JP2013526525A5 (https=) 2014-04-17

Family

ID=44314968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510219A Pending JP2013526525A (ja) 2010-05-11 2011-05-10 レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法

Country Status (6)

Country Link
US (4) US8404716B2 (https=)
EP (2) EP2568983A1 (https=)
JP (1) JP2013526525A (https=)
CN (1) CN103025330A (https=)
AU (1) AU2011253161B2 (https=)
WO (1) WO2011143147A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021125261A1 (https=) * 2019-12-18 2021-06-24
JP2022552882A (ja) * 2019-10-21 2022-12-20 セルジーン コーポレーション ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて血液悪性腫瘍を治療する方法
JP2022552883A (ja) * 2019-10-21 2022-12-20 セルジーン コーポレーション 血液がんの治療方法ならびに２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンに対するコンパニオンバイオマーカーの使用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
US20130244950A1 (en) * 2011-09-26 2013-09-19 Celgene Corporation Combination therapy for chemoresistant cancers
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
EP3171870B1 (en) 2014-07-24 2021-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10052346B2 (en) * 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017180768A1 (en) * 2016-04-15 2017-10-19 Seattle Genetics, Inc. Combinations of cd33 antibody drug conjugates with hypomethylating agents
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
BR112018075206A2 (pt) 2016-06-06 2019-03-19 Celgene Corporation tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
EP4324477A3 (en) 2016-12-08 2024-05-22 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
JP7017638B2 (ja) 2018-02-07 2022-02-08 ラブレス バイオメディカル リサーチ インスティテュート 吸入可能な乾燥粉末シチジン類似体組成物及び癌への治療として使用する方法
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2020046767A1 (en) * 2018-08-26 2020-03-05 Trovagene, Inc. Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
SG11202105506UA (en) * 2018-11-30 2021-06-29 Mei Pharma Inc Combination therapies for high and very high risk mds
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
CN109771643A (zh) * 2019-03-06 2019-05-21 厦门大学附属中山医院 儿童地中海贫血干细胞移植预处理联合化疗剂
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
WO2020219470A1 (en) * 2019-04-22 2020-10-29 Starton Therapeutics, Inc. Continuous delivery of lenalidomide and other immunomodulatory agents
AU2020381349A1 (en) * 2019-11-05 2022-04-28 F. Hoffmann-La Roche Ag Treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED DEGRADATION OF RET
MX2023008091A (es) 2021-01-08 2023-07-14 Starton Therapeutics Inc Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral.
WO2025024484A1 (en) * 2023-07-25 2025-01-30 Duke University Compositions and methods for treating blood cancer

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228601A (en) 1964-02-20 1966-01-11 Monarch Marking Systems Inc Controls for marking machine
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5974203A (en) 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5288487A (en) 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5354690A (en) * 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0505552A4 (en) 1990-10-12 1994-06-08 Amgen Inc Megakaryocyte maturation factors
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5641758A (en) 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0800680A4 (en) 1994-10-28 1998-08-12 Advanced Health Med E Systems PRESCRIPTION MANAGEMENT SYSTEM
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5619991A (en) 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
NZ333903A (en) 1996-07-24 2000-02-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
RU2188819C2 (ru) 1996-08-12 2002-09-10 Селджин Корпорейшн НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB
US5924074A (en) 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
NZ336035A (en) 1996-11-05 2002-03-28 Childrens Medical Center Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug
US6131090A (en) 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO1999010829A1 (en) 1997-08-22 1999-03-04 Deka Products Limited Partnership Health care system and method for physician order entry
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
EP1064277B1 (en) 1998-03-16 2005-06-15 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
JPH11286455A (ja) 1998-03-31 1999-10-19 Kanebo Ltd 骨髄異形成症候群治療薬
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
KR100672892B1 (ko) 1999-03-18 2007-01-23 셀진 코오퍼레이션 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
CN1361694A (zh) 1999-07-16 2002-07-31 天藤制药株式会社 粘膜吸收甘草甜素制剂
US6202923B1 (en) 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
MXPA02009665A (es) 2000-03-31 2005-09-08 Celgene Corp Inhibicion de actividad de ciclooxigenasa-2.
WO2001087306A2 (en) 2000-05-15 2001-11-22 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
BR0110877A (pt) 2000-05-15 2003-03-11 Celgene Corp Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
AU2001280161A1 (en) 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2003014315A2 (en) 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP4027693B2 (ja) 2002-03-20 2007-12-26 トリニティ工業株式会社 塗料送給装置及びバルブユニット
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CN102342938B (zh) 2002-05-17 2014-08-20 细胞基因公司 用于治疗和控制实体瘤的方法及组合物
EP1556033A4 (en) 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US20040162263A1 (en) 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US20040152632A1 (en) 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1744748A4 (en) 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
EP1744749A4 (en) 2004-04-14 2009-04-22 Celgene Corp METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP2211870A1 (en) 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5013007735; ＳＥＫＥＲＥＳ　ＭＩＫＫＡＥＬ　Ａ: 'ＦＩＮＡＬ　ＲＥＳＵＬＴＳ　ＦＲＯＭ　Ａ　ＰＨＡＳＥ　Ｉ　ＣＯＭＢＩＮＡＴＩＯＮ　ＳＴＵＤＹ　ＯＦ　ＬＥＮＡＬＩＤＯＭＩＤＥ　ＡＮＤ　ＡＺＡＣＩＴＩＤＩＮＥ　以下備考' ＢＬＯＯＤ Ｖ１１２　Ｎ１１, 200811, Ｐ８８-８９, ＡＭＥＲＩＣＡＮ　ＳＯＣＩＥＴＹ　ＯＦ　ＨＥＭＡＴＯＬＯＧＹ *
JPN6015004815; ＢＬＯＯＤ １１０, 2007 *
JPN6015004816; ＪＯＵＲＮＡＬ　ＯＦ　ＣＬＩＮＩＣＡＬ　ＯＮＣＯＬＯＧＹ ２８（１３）, 20100501, ｐ．２２５３-２２５８ *
JPN6015004818; 骨髄異形成症候群への理解：患者さんのためのハンドブック 第６版, 2009, ｐ．１-２９, 出版　骨髄異形成症候群財団 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552882A (ja) * 2019-10-21 2022-12-20 セルジーン コーポレーション ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて血液悪性腫瘍を治療する方法
JP2022552883A (ja) * 2019-10-21 2022-12-20 セルジーン コーポレーション 血液がんの治療方法ならびに２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンに対するコンパニオンバイオマーカーの使用
JP7581346B2 (ja) 2019-10-21 2024-11-12 セルジーン コーポレーション ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて血液悪性腫瘍を治療する方法
JP7662625B2 (ja) 2019-10-21 2025-04-15 セルジーン コーポレーション 血液がんの治療方法ならびに２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンに対するコンパニオンバイオマーカーの使用
JPWO2021125261A1 (https=) * 2019-12-18 2021-06-24
JP7653712B2 (ja) 2019-12-18 2025-03-31 一般社団法人東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬

Also Published As

Publication number Publication date
US20180207185A1 (en) 2018-07-26
AU2011253161B2 (en) 2014-07-24
AU2011253161A1 (en) 2012-11-22
US9056120B2 (en) 2015-06-16
US20130202590A1 (en) 2013-08-08
CN103025330A (zh) 2013-04-03
EP3219317A1 (en) 2017-09-20
EP2568983A1 (en) 2013-03-20
US20100278779A1 (en) 2010-11-04
US9925207B2 (en) 2018-03-27
WO2011143147A1 (en) 2011-11-17
US8404716B2 (en) 2013-03-26
US20150038444A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
US9056120B2 (en) Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1487461B1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) Methods of treating myelodysplastic syndromes using lenalidomide
US20080199422A1 (en) Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
US11116782B2 (en) Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
AU2014202561B2 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
HK1073427B (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
EP1900369A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
HK1117059A (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
NZ550831A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione or CC-4047 for the treatment and management of myelodysplastic syndromes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150929